CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-04-20 | Hagen Brett R Chief Accounting Officer | Sale 10b5-1 | −349 | $3.63 | $1K | 134,557 |
| 2023-04-19 | Sinha Vikas See Remarks | Sale 10b5-1 | −1,217 | $3.71 | $5K | 1,186,521 |
| 2023-04-19 | Hagen Brett R Chief Accounting Officer | Sale 10b5-1 | −348 | $3.71 | $1K | 134,906 |
| 2023-04-19 | Brainard Diana Chief Executive Officer | Sale 10b5-1 | −8,408 | $3.71 | $31K | 921,164 |
| 2023-03-01 | Adams Derek N. Director | Grant or award · Stock Option (Right to Buy) | +45,000 | 45,000 | ||
| 2023-02-21 | Brainard Diana Chief Executive Officer | Sale | −5,122 | $6.63 | $34K | 929,572 |
| 2023-02-02 | Sinha Vikas See Remarks | Grant or award | +157,500 | 1,187,738 | ||
| 2023-02-02 | Sinha Vikas See Remarks | Grant or award · Stock Option (Right to Buy) | +292,500 | 1,012,362 | ||
| 2023-02-02 | Miller Edward General Counsel | Grant or award | +87,500 | 235,958 | ||
| 2023-02-02 | Miller Edward General Counsel | Grant or award · Stock Option (Right to Buy) | +162,500 | 497,844 | ||
| 2023-02-02 | Leen Ann M. Chief Scientific Officer | Grant or award | +43,750 | 124,006 | ||
| 2023-02-02 | Leen Ann M. Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +81,250 | 473,594 | ||
| 2023-02-02 | Hagen Brett R Chief Accounting Officer | Grant or award | +61,250 | 135,254 | ||
| 2023-02-02 | Hagen Brett R Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +113,750 | 251,708 | ||
| 2023-02-02 | Brainard Diana Chief Executive Officer | Grant or award | +332,500 | 934,964 | ||
| 2023-02-02 | Brainard Diana Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +617,500 | 1,836,875 | ||
| 2023-01-20 | Sinha Vikas See Remarks | Sale | −1,426 | $5.14 | $7K | 1,030,238 |
| 2023-01-20 | Miller Edward General Counsel | Sale | −541 | $5.14 | $3K | 148,458 |
| 2023-01-20 | Hagen Brett R Chief Accounting Officer | Sale | −338 | $5.14 | $2K | 74,004 |
| 2023-01-19 | Sinha Vikas See Remarks | Sale | −5,111 | $5.08 | $26K | 1,031,664 |
Page 10 of 13 · 259 trades